Our Directors bring a wealth of business and industry experience, having worked for companies such as PwC, Deloitte, Citigroup and Promethera Biosciences. They are dedicated to maximising the clinical and commercial potential of our unique ECM scaffold technology.
Dr Steve Arlington
Dr Steve Arlington has served as Chairman of Engitix’s Board of Directors since November 2018, after joining as Non-Executive Director at the Company’s inception in 2016.
Dr Arlington has considerable experience of working in and consulting to the pharmaceutical and biotech industries. He is well known to many executives in the top 20 Pharmaceutical Companies, and whilst partner at PwC, he launched the highly acclaimed Pharma 2020 series among other thought leadership points of view.
Following a PhD in Immunopharmacology, Dr Arlington worked in R&D before joining PA Consulting Group, where he was Director of Healthcare, and subsequently PwC, where he became Lead Global Partner, Life Sciences and Pharmaceuticals.
Dr Arlington was also Global Services Life Sciences Leader at IBM from 2002-2005. He has worked part-time since retirement from PwC in 2014 and supports Genomics England, in addition to advising other businesses in the Life Sciences area.
He is a Fellow of the Royal Society of Medicine.
Dr Giuseppe Mazza
Chief Executive Officer and Co-Founder
Dr Giuseppe Mazza co-founded Engitix and has served as Chief Executive Officer (CEO) since the Company’s formation in 2016.
Engitix is built on Dr Mazza’s pioneering research, where he developed novel decellularisation procedures for human tissues, including whole livers, while working in the laboratory of Professor Massimo Pinzani at the Institute for Liver and Digestive Health (IDLH), Division of Medicine, University College London (UCL).
Dr Mazza was a Post-Doctoral Fellow at the UCL IDLH, where he was also responsible for operating the Tissue Engineering and Regenerative Medicine Laboratory. Dr Mazza received his PhD in Tissue Engineering and Organ Regeneration from the UCL. Dr Mazza was Director R&D at Promethera Bioscience from 2015 to 2017.
He has been involved in several international healthcare organizations, including serving on the Steering Committee of the non-profit European Haemophilia Consortium (EHC). In 2011, he founded the healthcare charity Associazione Icore ONLUS, where he served as President for six years.
Chief Financial Officer
David Dally joined Engitix as Chief Financial Officer (CFO) in November 2018.
Mr Dally has over 20 years of experience in the biotech and pharmaceutical industry, working in finance and general management across companies of varying size, financial ownership and geographical location, including in the UK, the US and Asia.
Mr Dally is an experienced executive having held the position of CEO at MerLion Pharmaceuticals since 2013, before which he was CFO from 2007. He was also consultant CEO for Reproductive Sciences Ltd from 2016 to 2018.
During his career, Mr Dally has been CFO for several companies including KuDOS Pharmaceuticals (which was sold to AstraZeneca for $210 million), Rhytec Ltd, and Dyson. He established his career as a financial leader through various roles at Amersham plc (now GE Healthcare), latterly as Vice President of finance, North America where he oversaw the merger of Amersham Life Science with Pharmacia Biotech.
David is a chartered accountant and holds a MA in Geography from the University of Cambridge.
Chief Operating Officer
Stephen Brindle has worked at Engitix as Chief Operating Officer (COO) since the Company was formed in 2016.
Before joining Engitix, he spent 8 years as Managing Partner of Technikos LLP, a medical devices venture capital fund with a long-term commercial contract with Oxford University’s Biomedical Engineering department.
Before Technikos Mr Brindle spent a decade as an equity salesman latterly with Citigroup and Goldman Sachs. Between 1991 and 1997 he worked as a management consultant, latterly at Deloitte Consulting.
He holds a BSc in Economics from LSE.
Professor Massimo Pinzani, MD, PhD, FAASLD
Professor Pinzani co-founded Engitix in 2016 and now serves on the Board of Directors.
With more than 30 years of experience in the field of hepatology and liver diseases as a Professor of Medicine and clinical and translational hepatologist, Professor Pinzani is an internationally renowned liver disease specialist. Since 2012, he has been Director of the UCL Institute for Liver and Digestive Health (ILDH) and the Sheila Sherlock Chair of Hepatology at UCL.
Professor Pinzani is a pioneer in research dedicated to cellular and molecular mechanisms of liver fibrosis and a key contributor to relative diagnostic and therapeutic approaches in the evaluation of disease progression. His research has continuously been funded by national and international organisations since 1994.
He serves as Chairman of the European Association for the Study of the Liver (EASL) Consortium for Regenerative Hepatology, following his roles as Educational Councillor and member of the Governing Board of EASL from 2015 to 2019.
Professor Pinzani has authored 200 original research publications,and served as Editor-in-Chief and Associate Editor, for several prestigious international peer-reviewed journals.